ABSTRACT
Background Anxiety disorders are associated with decreased heart rate variability (HRV), but the underlying mechanisms remain elusive.
Methods We selected individuals with whole-genome sequencing, Fitbit, and electronic health record data (N=920; 61,333 data points) from the All of Us Research Program. Anxiety PRS were derived with PRS-CS after meta-analyzing anxiety genome-wide association studies from three major cohorts-UK Biobank, FinnGen, and the Million Veterans Program (N Total =364,550). The standard deviation of average RR intervals (SDANN) was calculated using five-minute average RR intervals over full 24-hour heart rate measurements. Antidepressant exposure was defined as an active antidepressant prescription at the time of the HRV measurement in the EHR. The associations of daily SDANN measurements with the anxiety PRS, antidepressant classes, and antidepressant substances were tested. Participants with lifetime diagnoses of cardiovascular disorders, diabetes mellitus, and major depression were excluded in sensitivity analyses. One-sample Mendelian randomization (MR) was employed to assess potential causal effect of anxiety on SDANN.
Results Anxiety PRS was independently associated with reduced SDANN (beta=-0.08; p=0.003). Of the eight antidepressant medications and four classes tested, venlafaxine (beta=-0.12, p=0.002) and bupropion (beta=-0.071, p=0.01), tricyclic antidepressants (beta=-0.177, p=0.0008), selective serotonin reuptake inhibitors (beta=-0.069; p=0.0008) and serotonin and norepinephrine reuptake inhibitors (beta=-0.16; p=2×10−6) were associated with decreased SDANN. One-sample MR indicated an inverse effect of anxiety on SDANN (beta=-2.22, p=0.03).
Conclusions Anxiety and antidepressants are independently associated with decreased HRV, and anxiety appears to exert a causal effect on HRV. Our observational findings provide novel insights into the impact of anxiety on HRV.
Competing Interest Statement
Dr. Polimanti reported receiving personal fees for editorial work on the journal Complex Psychiatry from Karger Publishers and a research grant from Alkermes outside the submitted work. Dr. Stein reported consulting for Acadia Pharmaceuticals Inc, Aptinyx Inc, ATAI Life Sciences, Biogen Inc, Bionomics, BigHealth, BioXcel Therapeutics Inc, Boehringer Ingelheim, Clexio Biosciences Ltd, Eisai Co Ltd, EmpowerPharm, Engrail Therapeutics, Janssen Pharmaceuticals, Jazz Pharmaceuticals, NeuroTrauma Sciences LLC, PureTech Health, Sage Therapeutics, Sumitomo Pharma Co Ltd, and Roche-Genentech; and receiving stock options from Oxeia Biopharmaceuticals Inc and EpiVario outside the submitted work; serving as editor in chief for Depression and Anxiety, deputy editor for Biological Psychiatry, and co–editor in chief for Psychiatry for UpToDate for compensation. Dr. Lampert reported receiving speaker honoraria, advisory board fees, and research funding from Medtronic; speaker honoraria and research funding from Abbott/St Jude; and research funding from Boston Scientific. Dr. Miller reported consulting for Eidos, Pfizer, Siemens, Alnylam, and Roivant and receiving research funding from Eidos, Pfizer, and Argospect. No other disclosures were reported.
Funding Statement
This study was supported by grants from the National Institutes of Health (RF1 MH132337, R33 DA047527, T32 MH014276, and K99 AG078503) and One Mind.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All of Us Research Program
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Individual patient data are protected by All of Us Research Program Data Protection Policies, and thus cannot be made available.
